Literature DB >> 24900662

Discovery of Indenopyrazoles as a New Class of Hypoxia Inducible Factor (HIF)-1 Inhibitors.

Hidemitsu Minegishi1, Shinji Fukashiro1, Hyun Seung Ban1, Hiroyuki Nakamura1.   

Abstract

The indenopyrazole framework was investigated as a new class of HIF-1α inhibitors. Indenopyrazole 2l was found to most strongly inhibit the hypoxia-induced HIF-1α transcriptional activity (IC50 = 0.014 μM) among all of the known compounds having relatively simple structures, unlike manassantins. Indenopyrazole 2l suppressed HIF-1α transcriptional activity without affecting both HIF-1α protein accumulation and HIF-1α/HIF-1β heterodimerization in nuclei under the hypoxic conditions, suggesting that 2l probably affected the transcriptional pathway induced by the HIF-1α/HIF-1β heterodimer.

Entities:  

Keywords:  HIF-1; indenopyrazole; inhibitor; transcriptional activity

Year:  2013        PMID: 24900662      PMCID: PMC4027554          DOI: 10.1021/ml3004632

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  32 in total

1.  Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: its impact on prognosis and on neoangiogenesis.

Authors:  P Birner; B Gatterbauer; G Oberhuber; M Schindl; K Rössler; A Prodinger; H Budka; J A Hainfellner
Journal:  Cancer       Date:  2001-07-01       Impact factor: 6.860

2.  Saururus cernuus lignans--potent small molecule inhibitors of hypoxia-inducible factor-1.

Authors:  Chowdhury Faiz Hossain; Yong-Pil Kim; Scott R Baerson; Lei Zhang; Richard K Bruick; Kaleem A Mohammed; Ameeta K Agarwal; Dale G Nagle; Yu-Dong Zhou
Journal:  Biochem Biophys Res Commun       Date:  2005-08-05       Impact factor: 3.575

3.  HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing.

Authors:  M Ivan; K Kondo; H Yang; W Kim; J Valiando; M Ohh; A Salic; J M Asara; W S Lane; W G Kaelin
Journal:  Science       Date:  2001-04-05       Impact factor: 47.728

4.  Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer.

Authors:  P Birner; M Schindl; A Obermair; C Plank; G Breitenecker; G Oberhuber
Journal:  Cancer Res       Date:  2000-09-01       Impact factor: 12.701

5.  (Aryloxyacetylamino)benzoic acid analogues: A new class of hypoxia-inducible factor-1 inhibitors.

Authors:  Kyeong Lee; Jeong Hyung Lee; Shanthaveerappa K Boovanahalli; Yinglan Jin; Mijeoung Lee; Xuejun Jin; Jin Hwan Kim; Young-Soo Hong; Jung Joon Lee
Journal:  J Med Chem       Date:  2007-03-01       Impact factor: 7.446

6.  Identification of HSP60 as a primary target of o-carboranylphenoxyacetanilide, an HIF-1alpha inhibitor.

Authors:  Hyun Seung Ban; Kazuki Shimizu; Hidemitsu Minegishi; Hiroyuki Nakamura
Journal:  J Am Chem Soc       Date:  2010-09-01       Impact factor: 15.419

Review 7.  Angiogenesis: an organizing principle for drug discovery?

Authors:  Judah Folkman
Journal:  Nat Rev Drug Discov       Date:  2007-04       Impact factor: 84.694

8.  A novel benzimidazole analogue inhibits the hypoxia-inducible factor (HIF)-1 pathway.

Authors:  Mi-Sun Won; Namhui Im; Soohyun Park; Shanthaveerappa K Boovanahalli; Yinglan Jin; Xuejun Jin; Kyung-Sook Chung; Moorim Kang; Kiho Lee; Song-Kyu Park; Hwan Mook Kim; Byoung Mog Kwon; Jung Joon Lee; Kyeong Lee
Journal:  Biochem Biophys Res Commun       Date:  2009-05-09       Impact factor: 3.575

9.  Purification and characterization of hypoxia-inducible factor 1.

Authors:  G L Wang; G L Semenza
Journal:  J Biol Chem       Date:  1995-01-20       Impact factor: 5.157

10.  Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival.

Authors:  A Giatromanolaki; M I Koukourakis; E Sivridis; H Turley; K Talks; F Pezzella; K C Gatter; A L Harris
Journal:  Br J Cancer       Date:  2001-09-14       Impact factor: 7.640

View more
  7 in total

Review 1.  Hypoxia-induced alternative splicing in human diseases: the pledge, the turn, and the prestige.

Authors:  Subhashis Natua; Cheemala Ashok; Sanjeev Shukla
Journal:  Cell Mol Life Sci       Date:  2021-01-02       Impact factor: 9.261

2.  Transferrin receptor-involved HIF-1 signaling pathway in cervical cancer.

Authors:  Xiaofeng Xu; Tao Liu; Jun Wu; Yijin Wang; Ying Hong; Huaijun Zhou
Journal:  Cancer Gene Ther       Date:  2019-01-17       Impact factor: 5.987

Review 3.  Action Sites and Clinical Application of HIF-1α Inhibitors.

Authors:  Renfeng Xu; Fan Wang; Hongqin Yang; Zhengchao Wang
Journal:  Molecules       Date:  2022-05-26       Impact factor: 4.927

Review 4.  Development of Inhibitors Targeting Hypoxia-Inducible Factor 1 and 2 for Cancer Therapy.

Authors:  Tianchi Yu; Bo Tang; Xueying Sun
Journal:  Yonsei Med J       Date:  2017-05       Impact factor: 2.759

Review 5.  The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma.

Authors:  Song Peng; Jun Zhang; Xintao Tan; Yiqiang Huang; Jing Xu; Natalie Silk; Dianzheng Zhang; Qiuli Liu; Jun Jiang
Journal:  Front Endocrinol (Lausanne)       Date:  2020-11-24       Impact factor: 5.555

Review 6.  Targeting energy metabolism to eliminate cancer cells.

Authors:  Shazwin Hani Shahruzaman; Sharida Fakurazi; Sandra Maniam
Journal:  Cancer Manag Res       Date:  2018-07-31       Impact factor: 3.989

Review 7.  Hypoxia-induced alternative splicing: the 11th Hallmark of Cancer.

Authors:  Antonietta Rosella Farina; Lucia Cappabianca; Michela Sebastiano; Veronica Zelli; Stefano Guadagni; Andrew Reay Mackay
Journal:  J Exp Clin Cancer Res       Date:  2020-06-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.